PATENT Atty. Docket No. PP0938.105

I hereby certify that this paper is being deposited in the United States Postal Service as first class mail in an envelope addressed: BOX SEQUENCE, Assistant Commissioner of Patents and Trademarks, Washington, D.C.

202**%** April 10, 2002.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re Application of:

WEINER et al.

Serial No.:

08/823,980

Group Art: 1644

Filing Date

March 25, 1997

Examiner: R. Schwadron

For

CONSERVED MOTIF OF HEPATITIS C VIRUS E2/NS1 REGION

COMMUNICATION

Assistant Commissioner of Patents and Trademarks Washington, D.C. 20231

Sir:

In response to the "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures" mailed April 2, 2002, Applicants hereby submit a substitute paper copy of the sequence listing and a new computer-readable copy of the sequence listing containing section (1) (vii) as requested. Applicant's do not believe that a preliminary amendment is required as there are no changes to the specification.

Respectfully submitted,


Reg. No. 45,680

CHIRON CORPORATION Intellectual Property - R440 P.O. Box 8097 Emeryville, CA 94608 (510) 923-3179 (510) 655-3542 (Fax)

ECH CENTER 1600/2900



United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

ATTORNEY DOCKET NO. CONFIRMATION NO. APPLICATION NO. FILING DATE FIRST NAMED INVENTOR 03/25/1997 08/823,980 AMY J. WEINER CHIR-0108 8052 04/02/2002 7590 ALISA A. HARBIN, ESQ **EXAMINER CHIRON CORPORATION** SCHWADRON, RONALD B INTELLECTUAL PROPERTY **4560 HORTON STREET** PAPER NUMBER **ART UNIT** EMERYVILLE, CA 946082916 1644 Chica Supposing intellacied Proporty DATE MAILED: 04/02/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

RECEIVED

APR 1 9 2002

TECH CENTER 1600/2900

DOCKETED on/by 1802/6x.

Atty. APP PA 105

File # PP 00438 105

Due Date 5 2 102 Ext SL5

Einzl Date 10 12 102 SL0

PTO-90C (Rev. 07-01)





UNITED STATES DEPARTMENT OF COMMERCE Pat nt and Trad mark Offic COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

DATE MAILED:

			,		
SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT		ATTORNEY DOCKET NO.	
· · · · · · · · · · · · · · · · · · ·		RECEIVED		EXAMIN	IER
		APR 1 9 2002		1	
			ART UNI	T	PAPER NUMBER
		TECH CENTER 1600/2900			

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

The submitted CRF and Sequence in paper copy lack mandatory section (1) (vii) (see preJuly 1998 sequence rules, section 37 CFR 1.823(b)), wherein parent applications 08/757 958 and 08/061699 should be listed.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Any inquiry concerning this communication should be directed to Examiner Ron Schwadron, Ph.D., Art Unit 1644, whose telephone number is (703) 308-4680. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

RONALD B. SCHWADRON
PRIMARY EXAMINER
GROUP 1800 (6000)

Ron Schwadron, Ph.D.

Art Unit 1644

Application No.: 08/823980

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

X	attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
X	7. Other: See enciosED note
r	
Ap	plicant Must Provide:
Ap	plicant Must Provide: An <u>initial</u> or substitute computer readable form (CRF) copy of the "Sequence Listing".
Ap X	
N N	An <u>initial</u> or substitute computer readable form (CRF) copy of the "Sequence Listing". An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification. A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
X For	An <u>initial</u> or substitute computer readable form (CRF) copy of the "Sequence Listing". An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification. A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE